ALDERBRON, Goran,FORSLUND, Anders,HOLMBACK, Ulf,LENNERNAS, Hans,GRUDEN, Jan Stefan Persson
申请号：
PE0009812017
公开号：
PE12432017A1
申请日:
2015.12.17
申请国别(地区):
PE
年份:
2017
代理人:
摘要：
Refers to a modified release composition comprising orlistat and acarbose, which includes different portions with different Release patterns: a) a first part (G1, which comprises approximately 5 to 70% (W \/ W) of the total dose of acarbose, (b) a second part, G 2a, comprising approximately 30 to 95% w \/ W) of the total dose of acarbose, (c) a Third PartyG2B, comprising approximately (10 to 90% (W \/ W) of the total dose of orlistat, and (d) a Fourth part, G3, which comprises about 10% to about 80% p \/ p, P \/ p of the total dose of orlistat and the total concentration of acarbose and orlistat, respectively, in the composition of 100% p \/ p.Said composition is useful in the treatment of Metabolic Diseases such as obesity, Obesity and type 2 diabetesSe refiere a una composicion de liberacion modificada que comprende orlistat y acarbosa, que comprende partes individualmente distintas con diferentes patrones de liberacion: a) una primera parte, G1, que comprende aproximadamente (5 a 70)% p/p de la dosis total de acarbosa, b) una segunda parte, G2A, que comprende aproximadamente (30 a 95)% p/p de la dosis total de acarbosa, c) una tercera parte, G2B, que comprende aproximadamente (10 a 90)% p/p de la dosis total de orlistat, y d) una cuarta parte, G3, que comprende aproximadamente 10% p/p a aproximadamente 80% p/p de la dosis total de orlistat y la concentracion total de acarbosa y orlistat, respectivamente, en la composicion de 100% p/p. Dicha composicion es util en el tratamiento de enfermedades metabolicas tales como obesidad, sobrepeso y diabetes tipo 2
